Molecular Partners AG - ADR
NASDAQ:MOLN
| Market Cap (Intraday) | 250.86M |
| Current PE | 2.14 |
| Forward PE | 1.98 |
| 2yr Forward PE | N/A |
| 10-Day MA | $6.76 |
| 50-Day MA | $6.44 |
| 200-Day MA | $10.07 |
Molecular Partners AG - ADR Stock, NASDAQ:MOLN
Wagistrasse 14, Schlieren, Schlieren, Zurich 8952
Switzerland
Phone: +41.44.755.77.00
Number of Employees: 177
Description
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas PlÃ?Â?ckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.